Evidence map›Paper›PMID 34650558›Full record

ArticleFrontiers in immunology2021

Human Wharton's Jelly-Derived Mesenchymal Stromal Cells Primed by Tumor Necrosis Factor-α and Interferon-γ Modulate the Innate and Adaptive Immune Cells of Type 1 Diabetic Patients.

Mairvat Al- Mrahleh, Suzan Matar, Hanan Jafar, Suha Wehaibi, Nazneen Aslam, Abdalla Awidi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mairvat Al- MrahlehCell Therapy Center, The University of Jordan, Amman, Jordan.
Suzan MatarDepartment of Clinical Laboratory Science, The University of Jordan, School of Science, Amman, Jordan.
Hanan JafarCell Therapy Center, The University of Jordan, Amman, Jordan.
Suha WehaibiCell Therapy Center, The University of Jordan, Amman, Jordan.
Nazneen AslamCell Therapy Center, The University of Jordan, Amman, Jordan.
Abdalla AwidiCell Therapy Center, The University of Jordan, Amman, Jordan.
University of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unique immunomodulation and immunosuppressive potential of Wharton's jelly-derived mesenchymal stromal cells (WJ-MSCs) make them a promising therapeutic approach for autoimmune diseases including type 1 diabetes (T1D). The immunomodulatory effect of MSCs is exerted either by cell-cell contact or by secretome secretion. Cell-cell contact is a critical mechanism by which MSCs regulate immune-responses and generate immune regulatory cells such as tolerogenic dendritic cells (tolDCs) and regulatory T cell (Tregs). In this study, we primed WJ-MSCs with TNF-α and IFN-γ and investigated the immunomodulatory properties of primed WJ-MSCs on mature dendritic cells (mDCs) and activated T cells differentiated from mononuclear cells (MNCs) of T1D patient's. Our findings revealed that primed WJ-MSCs impaired the antigen-mediated immunity, upregulated immune-tolerance genes and downregulated immune-response genes. We also found an increase in the production of anti-inflammatory cytokines and suppression of the production of pro-inflammatory cytokines. Significant upregulation of

Indexed as

Adaptive ImmunityImmunity, InnateAdolescentAdultCell CommunicationCell DifferentiationCell ProliferationCells, CulturedCoculture TechniquesDendritic CellsDiabetes Mellitus, Type 1FemaleGene Expression RegulationHumansInterferon-gammaLymphocyte ActivationIFNG protein, humanInterferon-gammaTumor Necrosis Factor-alphaImmunomodulationprimingregulatory T cellstolerogenic dendritic cellstype 1 diabetesWharton’s jelly-derived mesenchymal stromal cells

Identifiers

PMID34650558
PMCPMC8506215
OpenAlexW3204528166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.